Marek Leszek Kowalski

Marek Leszek Kowalski

Auto-generated profile, based on publicly available information

Marek Leszek Kowalski

Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2013 in Allergy
Verified
Journal Article
Open access
PDF file
MKM. L. Kowalski
M. L. Kowalski
RAR. Asero
R. Asero
SBS. Bavbek
S. Bavbek
MBM. Blanca
M. Blanca
NBN. Blanca‐Lopez
N. Blanca‐Lopez
JMJ. Makowska
J. Makowska
Hypersensitivity reactions to aspirin (acetylsalicylic acid) and other nonsteroidal anti‐inflammatory drugs (NSAIDs) constitute only a subset of all adverse reactions to these drugs, but due to their severity pose a significant burden to patients and are a challenge to the allergist. In susceptible individuals, NSAIDs induce a wide spectrum of hypersensitivity reactions with various timing, organ manifestations, and severity, involving either immunological (allergic) or nonimmunological mechanisms. Proper classification of reactions based on clinical manifestations and suspected mechanism is a prerequisite for the implementation of rational diagnostic procedures and adequate patient management. This document, prepared by a panel of experts from the European Academy of Allergy and Clinical Immunology Task Force on NSAIDs Hypersensitivity, aims at reviewing the current knowledge in the field and proposes uniform definitions and clinically useful classification of hypersensitivity reactions to NSAIDs. The document proposes also practical algorithms for the diagnosis of specific types of NSAIDs hypersensitivity (which include drug provocations, skin testing and in vitro testing) and provides, when data are available, evidence‐based recommendations for the management of hypersensitive patients, including drug avoidance and drug desensitization.

14 February 2011 in Allergy
Verified
Journal Article
Open access
PDF file
MKM. L. Kowalski
M. L. Kowalski
JMJ. S. Makowska
J. S. Makowska
MBM. Blanca
M. Blanca
SBS. Bavbek
S. Bavbek
GBG. Bochenek
G. Bochenek
KBK. Brockow
K. Brockow
To cite this article: Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska‐Mogilnicka E, Romano A, Sanchez‐Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K. Hypersensitivity to nonsteroidal anti‐inflammatory drugs (NSAIDs) – classification, diagnosis and management: Review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011; 66: 818–829. Abstract Nonsteroidal anti‐inflammatory drugs (NSAIDs) are responsible for 21–25% of reported adverse drug events which include immunological and nonimmunological hypersensitivity reactions. This study presents up‐to‐date information on pathomechanisms, clinical spectrum, diagnostic tools and management of hypersensitivity reactions to NSAIDs. Clinically, NSAID hypersensitivity is particularly manifested by bronchial asthma, rhinosinusitis, anaphylaxis or urticaria and variety of late cutaneous and organ‐specific reactions. Diagnosis of hypersensitivity to a NSAID includes understanding of the underlying mechanism and is necessary for prevention and management. A stepwise approach to the diagnosis of hypersensitivity to NSAIDs is proposed, including clinical history, in vitro testing and/or provocation test with a culprit or alternative drug depending on the type of the reaction. The diagnostic process should result in providing the patient with written information both on forbidden and on alternative drugs.

14 September 2018 in Allergy
Verified
Journal Article
Closed access
PDF file
MKMarek L. Kowalski
Marek L. Kowalski
IAIoana Agache
Ioana Agache
SBSevim Bavbek
Sevim Bavbek
ABArzu Bakirtas
Arzu Bakirtas
MBMiguel Blanca
Miguel Blanca
AWAleksandra Wardzyńska
Aleksandra Wardzyńska

7 April 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
Jean BousquetJean Bousquet
Jean Bousquet
OPOliver Pfaar
Oliver Pfaar
ATAlkis Togias
Alkis Togias
HSHolger J. Schünemann
Holger J. Schünemann
IAIgnacio Ansotegui
Ignacio Ansotegui
TGthe ARIA Working Group
the ARIA Working Group

1 February 2016 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
PDF file
RORichard R. Orlandi
Richard R. Orlandi
TKTodd T. Kingdom
Todd T. Kingdom
PHPeter H. Hwang
Peter H. Hwang
TSTimothy L. Smith
Timothy L. Smith
JAJeremiah A. Alt
Jeremiah A. Alt
DKDavid W. Kennedy
David W. Kennedy

30 December 2016 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
Jean BousquetJean Bousquet
Jean Bousquet
PHP. W. Hellings
P. W. Hellings
IAI. Agache
I. Agache
ABA. Bedbrook
A. Bedbrook
CBClaus Bachert
Claus Bachert
MZM. Zidarn
M. Zidarn
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.